Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic melanoma with BRAF mutations is treatable with BRAF and MEK inhibitors.
• Resistance to these targeted therapies frequently emerges, limiting long-term efficacy.
• The mitogen-activated protein kinase (MAPK) pathway is crucial in melanoma pathogenesis.

Purpose of the Study:

• To review the MAPK pathway's biology in BRAF mutant melanoma.
• To detail clinical and molecular predictors of response to BRAF and MEK inhibitors.
• To discuss resistance mechanisms and future treatment strategies.

Main Methods:

• Literature review of BRAF and MEK inhibitors in BRAF mutant melanoma.
• Analysis of MAPK pathway signaling and resistance mechanisms.
• Synthesis of current and emerging treatment strategies.

Main Results:

• BRAF and MEK inhibitors are effective in approximately 40% of patients with BRAF mutant metastatic melanoma.
• Diverse clinical and molecular factors influence treatment response.
• Multiple mechanisms contribute to acquired resistance, including pathway reactivation and bypass signaling.

Conclusions:

• Understanding MAPK pathway biology is key to optimizing BRAF and MEK inhibitor therapy.
• Identifying predictors of response and resistance can guide personalized treatment approaches.
• Future strategies should address resistance to improve outcomes in BRAF mutant melanoma.